Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension

B. L. Pilmer, J. A. Green, Edward A Panacek, W. J. Elliot, M. B. Murphy, W. Rutherford, A. R. Nara

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Thirty-three patients with severe systemic hypertension defined as a diastolic blood pressure (DBP) ≥ 120 mm Hg were randomized in a single- blind fashion to be treated with either intravenous fenoldopam mesylate (FNP) or sodium nitroprusside (NTP). Fenoldopam mesylate and NTP infusion rates began at 0.1 μg/kg/minute and 0.5 μg/kg/minute, respectively and were titrated to achieve a goal DBP of between 95 and 110 mm Hg; or a reduction of at least 40 mm Hg if the baseline DBP was > 150 mm Hg. Fenoldopam mesylate (n = 15) reduced blood pressure from 217/145 ± 6/5 to 187/112 ± 6/3 mm Hg (P < .001) at an average infusion rate of 0.5 ± 0.1 μg/kg/minute. The average time to achieve goal DBP with FNP was 1.5 ± 1.4 hours. Nitroprusside (n = 18) reduced blood pressure from 210/136 ± 5/2 to 172/103 ± 6/2 mm Hg (P < .001) at an average infusion rate of 1.2 ± .24 μg/kg/minute. Nitroprusside response time averaged 2 ± 2.5 hours. There was no significant difference between the magnitude of effect seen with either FNP or NTP; nor was there any difference observed in the adverse effect rates of the two agents. Fenoldopam mesylate and NTP demonstrate similar overall efficacy in the treatment of severe systemic hypertension.

Original languageEnglish (US)
Pages (from-to)549-553
Number of pages5
JournalJournal of Clinical Pharmacology
Volume33
Issue number6
StatePublished - 1993
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pilmer, B. L., Green, J. A., Panacek, E. A., Elliot, W. J., Murphy, M. B., Rutherford, W., & Nara, A. R. (1993). Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension. Journal of Clinical Pharmacology, 33(6), 549-553.